1996
DOI: 10.1002/(sici)1097-0142(19960415)77:8<1707::aid-cncr43>3.0.co;2-0
|View full text |Cite
|
Sign up to set email alerts
|

Mutations of the p53 gene in the stool of patients with resectable colorectal cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
6
0
2

Year Published

1998
1998
2010
2010

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 66 publications
(9 citation statements)
references
References 11 publications
1
6
0
2
Order By: Relevance
“…Other such markers [21,22] may identify K-ras negative malignancies, thus further increasing the efficacy of the screening process. This process is similar in concept to several recently published studies of single or multiplexed, colorectal cancer associated gene mutations or gene silencing events on stool samples [8,13,[23][24][25][26][27] and on colon tissue [28].…”
Section: Discussionsupporting
confidence: 68%
“…Other such markers [21,22] may identify K-ras negative malignancies, thus further increasing the efficacy of the screening process. This process is similar in concept to several recently published studies of single or multiplexed, colorectal cancer associated gene mutations or gene silencing events on stool samples [8,13,[23][24][25][26][27] and on colon tissue [28].…”
Section: Discussionsupporting
confidence: 68%
“…3,26,27,28 DNA from tumor cells would be expected to represent a very small percentage of the total human DNA that is present in stool specimens, as the majority of cells would be expected to be normal epithelium. A further assumption of detection is that cancer and normal cells are equally likely to be sloughed and that their DNA is equally likely to remain intact in stool, a destructive and heterogeneous material.…”
Section: Discussionmentioning
confidence: 99%
“…In the last decade, a number of studies have reported neoplasm-specific DNA changes, up-regulation of some genes, and epigenetic changes in feces from patients with CRC or advanced adenomas (10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)39). A multitarget fecal DNA-based assay was recently reported to yield ∼90% positive results.…”
Section: Discussionmentioning
confidence: 99%
“…Recent advances in isolation of DNA directly from stool samples have allowed the analysis of genetic alterations associated with neoplasia (10)(11)(12)(13)(14)(15)(16). One study showed that the fecal DNA test is superior to guaiacbased FOBT for detecting CRC (16).…”
Section: Introductionmentioning
confidence: 99%